# Exosomes and Extracellular Vesicles: Signals Between Cells

> Cells release small membrane vesicles, and these extracellular vesicles can carry a signal from one cell to another, either as a ligand on their surface or as protein and RNA inside. The clearest case is antigen presentation: vesicles from B cells carry peptide-loaded MHC class II and stimulate only the matching T cells. One kind of vesicle, the exosome, is made inside a multivesicular body and let out when that body fuses with the cell surface. You will be able to explain how a vesicle can signal, say how an exosome is made, name three ways a vesicle could act on a target cell, and design the controls that separate a vesicle from whatever else comes down in the centrifuge.

Course: Cell Signaling (Space, time and distance). Level: advanced university and graduate. About 14 minutes.
Lesson page (link this one when citing): https://stemhop.com/lessons/exosomes-and-extracellular-vesicles/

Builds on: Endocytosis and Signaling Endosomes · Antigen Receptors and Checkpoints · A Field Guide to Receptors

## What you'll learn

- Explain how an extracellular vesicle can carry a signal from one cell to another, using vesicles from B cells that stimulate only the matching T cells as the worked case.
- Describe how an exosome forms inside a multivesicular body and is released when that body fuses with the plasma membrane, and distinguish it from a vesicle that buds from the cell surface.
- List what extracellular vesicles carry and name three ways a vesicle could act on another cell.
- Explain how vesicles are isolated, what else is in the pellet, and which controls separate a vesicle effect from a soluble factor.
- Evaluate cases where signalling by vesicles is well supported and one case where the claim is still argued.

**Cells release small membrane vesicles, and these extracellular vesicles can carry a signal from one cell to another.** The clearest case comes from the immune system: B lymphocytes release vesicles that carry peptide-loaded major histocompatibility complex (MHC) class II, and those vesicles stimulate only the T cells that recognise that peptide. This lesson starts from that case. Then it asks how such vesicles are made, the ways they could act, and how you would tell a real signal from an artefact of the centrifuge.

## Vesicles can carry a signal: the clearest case

Extracellular vesicles are small sacs of membrane that cells release into the fluid around them. A vesicle is a piece of membrane wrapped around a little of the cell’s interior, so it can carry two kinds of message: membrane proteins on its surface, and protein and RNA inside.

The clearest case comes from the immune system. B lymphocytes load peptides onto major histocompatibility complex (MHC) class II molecules, the proteins that display peptides to T cells, in compartments packed with small internal vesicles. In 1996 Graça Raposo and colleagues showed that B cells release those internal vesicles. The vesicles carried peptide-loaded MHC class II and stimulated T cells in culture, but only T cells whose receptor recognised that peptide on that MHC molecule. The specificity is the control, since a stray growth factor would not care which T cell it met.

*Figure (AI-generated illustration).* The clearest case: vesicles released by B cells carry peptide-loaded MHC class II on their surface and stimulate only T cells whose receptor recognises that peptide on that MHC molecule. The signal is a ligand meeting a receptor, so nothing has to enter the T cell. Image: a B cell releases small vesicles studded on their outer surface with MHC class II molecules holding a peptide. A vesicle docks on a T cell whose receptors match the peptide, and that T cell is stimulated; a second T cell with non-matching receptors does not respond. An inset shows the contact: the MHC-peptide on the vesicle meets the T cell receptor, and nothing enters the T cell.

Nothing had to enter the T cell. The vesicle acted as a whole B cell does when it presents antigen, by showing a ligand to a receptor. Two years later a group that included Raposo reported that vesicles from dendritic cells loaded with tumour peptides suppressed or eliminated established tumours in mice. How much such vesicles add to an immune response in the body is less clear.

Vesicles from other cells have since been reported to act in immune responses, tissue repair and cancer, and what they do depends on the cell that sent them and the cell that receives them.

## Where the vesicles come from: one compartment, two exits

You met the multivesicular body, also called the multivesicular endosome or MVE, earlier in this unit as the road to the lysosome. The membrane of an endosome buds inward, away from the cytosol, and pinches off small vesicles into its own interior, carrying ubiquitin-tagged receptors. If the compartment fuses with a lysosome, vesicles and cargo are digested.

The same kind of compartment has a second exit. It can move to the cell surface and fuse with the plasma membrane. Its internal vesicles are then outside the cell, intact, and those are exosomes. Picture a sorting room with two doors, one to the incinerator and one to the street. The word exosome therefore names an origin: a vesicle that formed inside a multivesicular body. The working description is short: one membrane, usually quoted as about 30 to 100 nanometres across (authors differ on the limits). That is too small to resolve in a light microscope.

*Figure (AI-generated illustration).* One compartment, two exits: a multivesicular body forms internal vesicles by budding inward, then either fuses with a lysosome, where they are digested, or fuses with the plasma membrane and releases them as exosomes. Because budding is away from the cytosol, a receptor on an exosome faces out as it did on the cell surface; microvesicles that bud straight from the surface have the same orientation. Image: a cut-away cell with a multivesicular body whose membrane buds inward, away from the cytosol, forming internal vesicles. One arrow leads to a lysosome where contents are digested; another leads to a multivesicular body fused with the plasma membrane, releasing its internal vesicles outside as exosomes. Separately, a microvesicle buds outward from the plasma membrane. An inset shows a released vesicle with a receptor whose head faces out.

The route was first seen in reticulocytes, red blood cells in their last stage of maturing. A reticulocyte still makes haemoglobin and takes in iron through the transferrin receptor, but a mature red cell makes no haemoglobin and carries essentially no transferrin receptors. In 1983 two laboratories reported that the receptors leave the cell on vesicles about 50 nanometres across; rat images from that year and sheep micrographs from 1985 showed multivesicular bodies fusing with the cell surface and releasing them, and in 1987 Rose Johnstone’s group named those vesicles exosomes and read them as a way to discard proteins the cell no longer needed. The B-cell compartments where major histocompatibility complex (MHC) class II is loaded are multivesicular too, and they release their internal vesicles the same way.

The inward budding is done by protein complexes called ESCRT, with partners such as ALIX. Some cargo can be loaded by other routes, one of which depends on the lipid ceramide, and in some cells small GTPases of the Rab family are needed for the compartment to dock at the surface. Which of these a cell needs varies with the cell, and what chooses the door is only partly known.

The direction of budding fixes the geometry. Because the bud forms away from the cytosol, the inside of an exosome is a sample of cytosol, and its outer face is the face that was the outside of the cell. A receptor on an exosome points its ligand-binding domain outward, as it did on the plasma membrane. That is why a vesicle can present an MHC molecule, or any other surface ligand, to another cell the right way out.

Cells also release vesicles that bud straight outward from the plasma membrane, called microvesicles or ectosomes. They have the same orientation and overlap in size, so once both kinds are in the medium no agreed test reliably tells them apart. The usual markers of small vesicles are tetraspanins such as CD9, CD63 and CD81, membrane proteins with four membrane-spanning helices, and they are found on both kinds. For that reason the field’s own society, ISEV, urges authors to use “extracellular vesicle”, or a descriptive term such as “small extracellular vesicle”, unless they can show where a vesicle was made. Synaptic vesicles are a different thing: they stay inside the neuron, release a soluble transmitter when they fuse with the surface, and are recycled.

## What is inside, and three ways it could act

Vesicles carry membrane proteins, receptors among them, cytosolic proteins, the lipids of their own membrane, and RNA. The proteins follow from the geometry. Messenger RNA and microRNA drew the most attention. In 2007 Jan Lötvall’s laboratory found messenger RNA and microRNA (a short RNA that lowers the output of matching messenger RNAs) in exosome preparations from mast cells, a kind of immune cell, and when vesicles from mouse mast cells were added to human mast cells, mouse proteins were detected in the human cells. But in carefully purified small vesicles most of the RNA is transfer RNA and other small non-coding RNAs. Later counting set a limit on the picture: a 2014 study found far less than one copy of any given microRNA per vesicle on average.

A vesicle could act on another cell in three ways, and each needs different evidence.

1. **By a ligand on its surface.** A protein on the vesicle binds a receptor on the target cell. Nothing has to get in: this is ordinary receptor signalling with the ligand held on a membrane. The B-cell vesicles work this way. One vesicle can display many copies of a membrane protein, so this route does not run into the copy-number limit that applies to RNA.
2. **By fusing.** The vesicle membrane merges with a membrane of the target cell, at the surface or from inside an endosome, and the contents enter the cytosol. This is the best-studied route by which an RNA or a cytosolic enzyme could act there; escape from a leaky endosome has also been proposed.
3. **By being taken up.** The target cell swallows the vesicle by endocytosis. On its own this shows little, because the usual fate of what a cell swallows is the lysosome. A vesicle that has been eaten has signalled only if something it carries is sensed on the way or escapes.

*Figure (AI-generated illustration).* Three ways a vesicle could act on another cell. A ligand on its surface needs nothing to get in; fusion is the main proposed route that puts contents in the cytosol; uptake alone usually ends at the lysosome. Image: three panels show a small vesicle acting on a target cell by a surface ligand binding a receptor, by fusing and releasing its contents into the cytosol, and by being taken up into an endosome that leads to a lysosome.

## How would you know? The pellet is defined by the centrifuge

**Film transcript: The Pellet Is Defined By The Centrifuge**

### Film transcript: The Pellet Is Defined By The Centrifuge

How would you know that a vesicle carries a message? Start with how vesicles are collected. Slow spins remove cells and debris. A faster spin removes large vesicles. About 100,000 times gravity, for an hour or more, brings down the small ones. The pellet holds everything of the right size and density, whatever it is. That includes protein aggregates, lipoprotein particles, viruses, and vesicles from the calf serum in the medium. Soluble growth factors can stick to any of these. These contaminants have changed conclusions. In 2019, Robert Coffey's laboratory separated such pellets further. Argonaute proteins, which carry microRNA, were not detected in the exosomes.

So a claim needs controls. Purify further, most often by floating the pellet on a sucrose density gradient. Membrane vesicles rise to about 1.13 to 1.19 grams per millilitre. Free protein stays below. Ask whether the activity moves with the vesicles. Test the supernatant left after the spin, and a pellet from medium that never saw cells. And count. Copies per vesicle is cargo copies measured, divided by particles counted. If that number is far below one, or if the effect needs many more vesicles than the donor cells release, the case for signalling is weak, however clean the pellet. Your turn. Spin the medium from cell type A, add the pellet to cell type B, and B changes.

Which controls do you need?

Vesicles are isolated by spinning. Slow spins remove cells and debris, a faster spin removes large vesicles, and about 100,000 times gravity for an hour or more brings down the small ones. What comes down is everything of the right size and density, whatever it is: protein aggregates, lipoprotein particles, complexes of RNA and protein, viruses, vesicles from the calf serum in the culture medium, and soluble growth factors stuck to any of these.

The contaminants have changed conclusions. In 2019 Robert Coffey’s laboratory separated such pellets further on [density gradients](https://stemhop.com/methods/subcellular-fractionation/), and separately captured vesicles on antibodies from medium that had not been spun at high speed, and found that Argonaute proteins, which carry microRNA, were not detected in the exosomes, and that small vesicles were not vehicles of active DNA release.

So a claim needs controls. Purify further, for example by floating the pellet on a density gradient, where small vesicles in sucrose usually rise to about 1.13 to 1.19 grams per millilitre and free protein stays below, and ask whether the activity moves with the vesicles. Test the supernatant left after the spin, and a pellet from medium that never saw cells. Ask whether the cargo is inside: a protein or RNA within a vesicle survives protease or ribonuclease (RNase) until detergent opens the membrane. And count.

> **copies per vesicle = copies of the cargo measured ÷ particles counted**

If that number is far below one, or if the effect needs many more vesicles than the donor cells release, the case for signalling is weak however clean the pellet.

### Design problem

You spin the medium from cell type A, add the pellet to cell type B, and B changes its behaviour. Design the controls you need before you may say that exosomes from A carried a signal to B. Name at least three other explanations, and the experiment that removes each one.

> **One way to do it.** **The serum did it.** Calf serum in the medium brings its own vesicles and growth factors. Grow A without serum, or in serum depleted of vesicles (a long spin leaves much of the serum’s own RNA behind), and make a mock pellet from medium that sat in a dish with no cells. If the mock pellet changes B as much as the real one, the medium and not A is the source.
>
> **A soluble factor came down with the pellet.** A cytokine from A may have aggregated or stuck to vesicles. Float the pellet on a density gradient and test every fraction on B. The activity should peak where the vesicle markers and the particle count peak.
>
> **A contaminant did it.** If B is an immune cell, a trace of bacterial lipopolysaccharide will switch on Toll-like receptor 4. Test the pellet for lipopolysaccharide and repeat with cells of type B that lack the receptor.
>
> **The vesicles did it, at a dose no cell would meet.** Count the particles you add, compare with what A releases in the same time, and titrate down. Then make the claim specific: a pellet from A cells that lack the candidate cargo should fail, though deleting a gene can change the donor cell and the rest of its vesicles, so check those too.
>
> With all four done you have a strong case for a signal carried on vesicles from A. To say exosomes, you must also show that the vesicles came from a multivesicular body.

## Where the evidence is good, and where it is argued

**Antigen presentation.** This is the strongest case, set out at the top of this lesson. The T cell response followed the peptide and the major histocompatibility complex (MHC) molecule, which a stray soluble factor would not do, and the signal is a ligand on a surface, so nothing has to get in. How much such vesicles add to an immune response in the body is still less clear.

**Disposal.** The reticulocyte case stands, and no message is needed to explain it.

**Axon repair.** Schwann cells are the glia that wrap peripheral axons. Vesicles from cultured Schwann cells are taken up by sensory axons and speed their regrowth, in culture and after nerve injury. The evidence is direct, but it rests on adding prepared vesicles, so count it as supported and not yet closed.

**“Cancer uses exosomes to evade therapy.”** Weigh this as a claim. Tumour vesicles can carry programmed death-ligand 1 (PD-L1), the ligand for the checkpoint receptor PD-1. In one [mouse model](https://stemhop.com/methods/animal-disease-models/) of prostate cancer, tumour cells with Rab27a deleted, which release far fewer exosomes, failed to grow in mice with a working immune system but grew in mice without one. The same study also deleted PD-L1 itself, and exosomal PD-L1 injected into the mice restored growth of tumours that could not secrete their own. Tumour vesicles have also been reported to act as decoys for antibody drugs, and PD-L1 on circulating vesicles has been followed in people with melanoma during treatment. The size of the effect in patients is uncertain.

**As tools.** Vesicles in blood and urine carry proteins and RNA from the tissues that made them, so they are being tested as markers of disease that a blood sample can reach. Groups are also loading vesicles with drugs or RNA. Both uses depend on knowing exactly what is in the tube.

## Going deeper

### How the route was found

The reticulocyte has lost its nucleus but still needs iron, which arrives on the blood protein transferrin.

In 1983 two laboratories reported where its receptors go. In St. Louis, Clifford Harding, John Heuser and Philip Stahl coupled transferrin to particles of gold, which show as black dots in the [electron microscope](https://stemhop.com/methods/electron-microscopy/), and followed it into rat reticulocytes. The gold reached endosomes and then appeared in a compartment packed with small vesicles (about 50 nanometres across, by the authors’ later account), with the gold on them. Some of these compartments appeared to have fused with the plasma membrane, and their small vesicles were outside the cell. In Montreal, Bin-Tao Pan and Rose Johnstone cultured sheep reticulocytes and found that the receptor lost from the cells turned up in the medium, on vesicles they could collect in a centrifuge. Their electron micrographs of 1985 showed the same route in the sheep cells. In 1987 Johnstone’s group used the name **exosome** for these vesicles.

### What sets the door

In a mouse oligodendrocyte cell line, loading one myelin protein into the internal vesicles needed the lipid ceramide and not ESCRT. In the human cell line HeLa, the small GTPases Rab27a and Rab27b were needed for multivesicular bodies to dock at the surface. Each result holds for the cells it was measured in.

### Early reports of RNA in vesicles

Messenger RNA in vesicles from embryonic stem cells was reported in 2006, a year before the mast cell study from Jan Lötvall’s laboratory in Gothenburg.

### Axon repair in detail

The laboratory of Felipe Court proposed in 2012, and reported with data in 2013, that vesicles from cultured Schwann cells are taken up by sensory axons, speed their regrowth in culture and after injury to the sciatic nerve, and lower the activity of the GTPase RhoA, which is involved in growth cone collapse.

### Cancer: decoys, a marker in blood, and the Rab27a question

Tumour vesicles have been reported to carry the target of an antibody drug, such as HER2 or CD20, and to bind the antibody before it reaches the cell. The decoy experiments were done mostly in culture, where the experimenter chooses the dose. In one study of people with melanoma, the size of the early rise in programmed death-ligand 1 (PD-L1) on circulating vesicles during anti-PD-1 treatment separated responders from non-responders. A correlation in blood cannot show whether vesicle PD-L1 alters the response or reflects the amount of tumour; the authors themselves read the early rise as the tumour responding to reactivated T cells. In the prostate cancer study, Rab27a, one of the genes deleted to block release, has other jobs in secretion, which is why the deletion of PD-L1 itself and the rescue with injected exosomal PD-L1 carry the argument.

### Loading vesicles with RNA

A 2011 report from Matthew Wood’s laboratory described engineered vesicles delivering a gene-silencing RNA to the mouse brain, although a 2013 study with Wood among its authors showed that the method used to load such RNA can form aggregates that make loading look more efficient than it is.

---

From STEMhop (https://stemhop.com), free lessons by Christopher Deppmann. Lesson text © the authors. Practice questions: https://stemhop.com/lessons/exosomes-and-extracellular-vesicles/
